Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
16 Feb 2018
Change (% chg)

$0.00 (+1.96%)
Prev Close
$0.25
Open
$0.27
Day's High
$0.28
Day's Low
$0.26
Volume
124,191
Avg. Vol
175,022
52-wk High
$1.96
52-wk Low
$0.23

Select another date:

Mon, Feb 12 2018

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017

BRIEF-Contravir Pharmaceuticals enters research collaboration with Li Ka Shing Institute of Virology

* Contravir Pharmaceuticals announces research collaboration agreement with Li Ka Shing Institute of Virology Source text for Eikon: Further company coverage: (Reporting by Sruthi Ramakrishnan)

BRIEF-Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.

* Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States

BRIEF-U.K. accepts Contravir Pharma's clinical trial application

* Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom

BRIEF-ContraVir Pharmaceuticals announces issuance of new U.S. patent for expansion of cyclophilin inhibitor program

* ContraVir Pharmaceuticals announces issuance of new US patent for expansion of cyclophilin inhibitor program

Select another date: